article thumbnail

MIT Reveals 2025 Breakthrough Tech At SXSW: What It Means For Legal

Above The Law

Friday morning at SXSW , Niall Firth , the Executive Editor of the Newsroom at the Massachusetts Institute of Technology (MIT), reviewed MITs annual list of 10 breakthrough technologies for 2025. The Top Ten Breakthrough Technologies for 2025 Here are the ten technologies that made this years list: Vera C.

Legal 111
article thumbnail

Supreme Court Patent Challenges February 2025

Patently O

by Dennis Crouch The Supreme Court's 2024-2025 patent docket has a growing number of cases awaiting consideration. Two cases raise what I see as core substantive patent law issues outside of eligibility: Converter Manufacturing questions the court's long-standing approach to prior art enablement.

Court 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CMS Finalizes Guidance on Medicare Part D Manufacturer Discount Program

FDA Law Blog

As part of this change, the Coverage Gap Discount Program (CGDP), a program that has existed since 2011, will sunset on December 31, 2024, and be replaced by the Medicare Part D Manufacturer Discount Program (the “Discount Program”). CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028.

article thumbnail

Biologics Patent Enforcement: Regeneron Patents Block Biosimilar Entry for EYLEA

Patently O

29, 2025) (precedential); and Regeneron Pharms., 29, 2025) (nonprecedential). The cases pit Regeneron against foreign manufacturers, including Samsung Bioepis (SB) and Formycon AG, who had obtained FDA approval for their biosimilar products under the Biologics Price Competition and Innovation Act (BPCIA). Regeneron Pharms.,

article thumbnail

Justices schedule major First Amendment case for January

SCOTUSBlog

21) – Whether a manufacturer can file a petition for review in a circuit where it does not reside or have its principal place of business as long as it is joined by a seller of its products that is located within that circuit. Share The Supreme Court will hear an important First Amendment case on Jan. 13 and continues until Jan. Paxton (Jan.

article thumbnail

When Properties Define Structure: Eligibility of Composition Claims

Patently O

As I wrote in an October 2024 post, this case raised fundamental questions about whether composition of matter claims could ever be considered abstract ideas simply because they included functional limitations or defined the composition through its properties rather than manufacturing steps. US Synthetic Corp. Int'l Trade Comm'n , No.

article thumbnail

Design-Around Victory: Amgen’s Self-Buffering Innovation Regeneron’s Claims

Patently O

14, 2025) (Lourie, J.). This latest ruling stands in contrast to the court's January 2025 decisions upholding preliminary injunctions against Samsung Bioepis and Formycon, effectively blocking their biosimilar launches. Regeneron Pharms., Mylan Pharms. 2024-2351 (Fed.